US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AI Healthcare

718.58

+34.395.03%

Number of Gainers:4

Number of Losers:- -

Number of Flat:- -

PE:- -

High:723.60

Open:686.41

Low:684.21

Close:684.19

Volume:25.09M

Turnover:636.05M

Market Cap:23.63B

Float Cap:18.09B

Loading ...

Crispr Therapeutics Grants Chief Technical Officer 90,000 Stock Options, 40,000 Restricted Stock Units

Alphabet's Q3 13F Revealed: Keeps Adding to Top Holdings SpaceX (SPCX.US), Takes Roughly $548 Million Stake in Qualcomm (QCOM.US)

Tempus AI, Inc. (NASDAQ:TEM) Just Reported And Analysts Have Been Lifting Their Price Targets

Simply Wall St.

Recursion Stock Gets A Lift From Trial Progress And New Board Chair

Simply Wall St.

Beam Therapeutics Inc. : Jonestrading Assumes Coverage with Buy Rating; Target Price $35

THOMSON REUTERS

Recursion Pharmaceuticals Grants Director Fred Hassan 156,658 Restricted Stock Units

Recursion Pharmaceuticals Director Blake Borgeson Reports Sale of $155,200 in Common Shares

Tempus AI Director David R Epstein Reports Sale of Common Shares Worth $27,487.30

Personalis Q3 Revenue Beat on Increased Test Volume; Suspends Forecast on Pending Tempus AI Merger

Crispr Therapeutics Presents Zugo-Cel Lymphoma Data at ASH Annual Meeting

Beam Therapeutics Reports Improved Patient-Reported Outcomes in Risto-Cel Sickle Cell Trial

Clene Posts Q3 Profit on Warrant Liability Gains

Analysts Have Conflicting Sentiments on These Healthcare Companies: Alkermes (ALKS), Nurix Therapeutics (NRIX) and Beam Therapeutics (BEAM)

Beam Therapeutics Inc. : Wedbush Raises Target Price to $30 from $28

THOMSON REUTERS

Viridian Posts First Lumvoa Revenue but Net Loss Widens

Ocugen Q3 Revenue Beats Expectations, Net Loss Narrows

Switzerland's MoonLake Q3 Net Loss Widens as R&D Costs Rise

AC Immune Q3 Net Loss Narrows as Revenue Rises

Nuvectis Pharma Q3 Net Loss Widens on Licensing and R&D Costs

Q32 Bio Q3 Net Loss Widens on Higher R&D and Admin Costs

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www-web.itiger.com/stock/BK4611/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4611","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","market":"US","secType":"PLATE","nameCN":"AI Healthcare","latestPrice":718.5793,"timestamp":1793998799999,"preClose":684.1918,"halted":0,"volume":25093991,"delay":0,"changeRate":0.05026,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":34.387512,"latestTime":"11-06 16:00:00 EST","open":686.40643,"high":723.6038,"low":684.207,"amount":636046799.264789,"amplitude":0.057582,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794214800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.18728,"peRate":-16.515541,"turnoverRate":0.027649,"increases":4,"decrements":0,"flats":0,"marketCap":23632982528,"floatMarketCap":18090149760},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","high":723.6038,"amplitude":0.057582,"preClose":684.1918,"low":684.207,"pbRate":"5.18728","latestPrice":718.5793,"volume":25093991,"delay":0,"open":686.40643,"prevYearClose":658.3995,"prevWeekClose":719.6765,"prevMonthClose":719.6765,"prevQuarterClose":771.3898,"fiveDayClose":719.6765,"twentyDayClose":721.3771,"sixtyDayClose":625.3489,"secType":"PLATE","market":"US","turnoverRate":0.027649,"peRate":-16.515541,"marketCap":23632982528,"floatMarketCap":18090149760,"timestamp":1793998799999,"nameCN":"AI Healthcare"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4611\",,,,undefined,":{"bkCode":"BK4611","up":4,"down":0,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4611\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2681889710","title":"Crispr Therapeutics Grants Chief Technical Officer 90,000 Stock Options, 40,000 Restricted Stock Units","url":"https://stock-news.laohu8.com/highlight/detail?id=2681889710","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681889710?lang=en_us&edition=fundamental","pubTime":"2026-11-07 06:35","pubTimestamp":1794004554,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics grants chief technical officer 90,000 stock options, 40,000 restricted stock unitsCRISPR Therapeutics granted Chief Technical Officer Sivakesava Sakhamuri 90,000 stock options on N","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261106:nNDL71p457:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARKG","BK4556","LU1861558580.USD","BK4588","BK4611","BK4139","LU1861559042.SGD","CRSP","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113338385","title":"Alphabet's Q3 13F Revealed: Keeps Adding to Top Holdings SpaceX (SPCX.US), Takes Roughly $548 Million Stake in Qualcomm (QCOM.US)","url":"https://stock-news.laohu8.com/highlight/detail?id=1113338385","media":"Stock News","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113338385?lang=en_us&edition=fundamental","pubTime":"2026-11-06 21:41","pubTimestamp":1793972471,"startTime":"0","endTime":"0","summary":"According to a disclosure by the U.S. Securities and Exchange Commission (SEC), Google parent Alphabet (GOOGL.US) filed its third-quarter U.S. equity holdings report (13F) for the period ended...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1084165304.USD","LU2264538146.SGD","LU0353189763.USD","LU2403377893.USD","IE00BKPKM429.USD","LU0528227936.USD","LU1585245621.USD","IE00BQXX3F31.USD","LU2063271972.USD","LU0345770308.USD","LU0316494557.USD","IE000F7OJYX1.SGD","LU0211331839.USD","ASUP","LU0312595415.SGD","LU2360107168.USD","LU1791710582.SGD","HK0000819398.USD","LU0648000940.SGD","LU0096362180.USD","LU0820561818.USD","GOOP","FTXL","LU2098885051.SGD","IDNA","LU0234570918.USD","LU2168564222.USD","LU0708995401.HKD","LU2430703095.HKD","BK4579","LU0494093205.USD","OGIG","LU2491050071.SGD","LU1861559042.SGD","LU0342679015.USD","GTLB","BK4077","LU0069063385.USD","SPAX","LU0198837287.USD","LU0898699433.AUD","LU1674673691.USD","RVMD","LU0310800379.SGD","LU1429558221.USD","LU0772969993.USD","LU0661504455.SGD","LU2290526834.HKD","IE0034235303.USD","BK4574","LU0738911758.USD","LU1221951129.SGD","LU1551013425.SGD","IE00B42XCP33.USD","UFO","LU0251132253.USD","BK4612","IE00B7SZLL34.SGD","LU2592432038.USD","LU0061474705.USD","LU1599440770.SGD","LU2491050154.USD","LU2326559502.SGD","LU1043141123.HKD","LU1043141396.HKD","LU2089284900.SGD","SG9999018865.SGD","LU1228905037.USD","LU0314106906.USD","FRNM","LU0889565916.HKD","ASTG","ASTS","BK4139","LU1066051811.HKD","YSPC","LU0157215616.USD","BK4607","SG9999000418.SGD","ASTN","LU0444973449.USD","LU0310799852.SGD","LU0128525689.USD","LU0210533765.USD","LU1496350502.SGD","IE0034235188.USD","LU2362540622.SGD","LU2028103732.USD","CQTM","LU0985320562.USD","SNPE","LU0203347892.USD","SPRO","LU1551013342.USD","LU1699723380.USD","LU0310800965.SGD","GB00B4QBRK32.GBP","WSPC","IE00BFTCPJ56.SGD","LU2092627202.USD","LU0353189680.USD","LU0742537680.HKD","LU1228905540.USD","LU0820562030.AUD","SPCG","BK4588","LU2347655156.SGD","GGLS","LU0080751232.USD","LU0208291251.USD","PBLS","LU0823421333.USD","LU0154236417.USD","LU0061474960.USD","VOX","IE0009355771.USD","IE00B4R5TH58.HKD","LTL","IE00B19Z9505.USD","IE00BVYPNQ40.USD","LU1506573853.SGD","LU2102340556.USD","SG9999001424.SGD","LU0426417589.USD","LU2265009873.SGD","LU2506952170.USD","LU0823417737.USD","LU0267386448.USD","IE00BHPRN162.USD","LU0949170426.SGD","BK4566","LU0048573561.USD","LU1868837300.USD","LU1989772840.SGD","LU1935042488.USD","LU2092937148.SGD","LU0726765562.USD","LU1366192091.USD","LU1481011671.HKD","LU0079474960.USD","LU0053671581.USD","SG9999014567.USD","LU0348723411.USD","LU0107464264.USD","LU0868494617.USD","IE00BMPRXN33.USD","LU0057025933.USD","PTH","LU0496365809.HKD","CME","LU0265550359.USD","LU0683600562.USD","SPCF","IE00B19Z3581.USD","LU0690374961.EUR","LU2756315318.SGD","LU1629891620.HKD","TEMC","LU1236620750.USD","LU0158827948.USD","SPCM","LU1400636574.HKD","LU0211328371.USD","LU0942090050.USD","IE000SO60NU8.SGD","IE00BGHQF631.EUR","LU2168564149.EUR","IE00BJLML261.HKD","LU1988902786.USD","LU0345769128.USD","LU0648001328.SGD","LU1435385759.SGD","IE000BZT7R73.USD","LU0943347566.SGD","SG9999014575.USD","IE00B3PB1722.GBP","HK0000914660.USD","LU1153585028.USD","SPRX","LU1032955483.USD","LU1674673428.USD","LU0640476718.USD","LU1732799900.SGD","LU0912757837.SGD","LU1400636491.USD","BK4573","QQQA","IE0004086264.USD","LU1202635105.USD","LU0708994859.HKD","LU2471134796.USD","LU2750360997.AUD","SGXZ99366536.SGD","LU2168564495.EUR","BK4611","LU2506951875.HKD","LU0731783048.USD","LU0823417653.USD","LU2381873111.SGD","LU0251131958.USD","LU2097344431.USD","BK4602","LU0949170772.SGD","LU1267930813.SGD","LU0211327993.USD","SGXZ44715902.SGD","LU1003077747.HKD","SG9999014559.SGD","LU2505996681.GBP","SG9999015341.SGD","GOOL","SPCQ","QCOM","ARMW","LU0029864427.USD","LU1989764664.SGD","HK0000914686.HKD","LU0823434740.USD","FCOM","SQCOMmain","LU0642271901.SGD","BK4598","LIME","LU0792757196.USD","LU0417517546.SGD","LU1116320901.HKD","ORBX","LU1670756490.USD","LU2087621335.USD","LU2089283258.USD","LU2125909247.SGD","LU2087625088.SGD","BK4581","LU0395794307.EUR","LU2505996509.AUD","LU1861220033.SGD","IE00BLSP4239.USD","LU0957808578.USD","LU1066053197.SGD","LU2860962120.EUR","LU0048584097.USD","IE00BVYPNV92.GBP","LU0056508442.USD","LU0130103400.USD","LU1868836591.USD","PL","ASTT","LU0094547139.USD","LU2125154935.USD","LU2244417387.USD","LU2471134952.CNY","ARKG","IE00BLSP4452.SGD","LU2360106780.USD","LU2360032135.SGD","LU0314104364.USD","LU2602419157.SGD","IE000MB6IJN5.SGD","LU0823434583.USD","BK4123","LU1064131342.USD","LU0256863811.USD","LU1791710400.SGD","LU1316542783.SGD","IE00B3T34201.USD","GXPC","LU0138981039.USD","BK4141","SG9999015978.USD","LU2065171311.SGD","SG9999014898.SGD","LU1509826696.USD","LU0211326839.USD","LU2404859741.USD","LU0251142724.SGD","GOOX","LU0545039389.USD","LU1116320737.USD","GB00B4LPDJ14.GBP","LU1323610961.USD","LU2236285917.USD","SGXZ80539844.SGD","LU0289739343.SGD","LU0994945656.USD","IE00BN8TJ469.HKD","LU0225283273.USD","LU1267930490.SGD","LU1670627923.USD","LU0289961442.SGD","BK4604","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","SG9999015952.SGD","LU1232071149.USD","LU0109394709.USD","LU0203345920.USD","BK4121","LU1261432733.SGD","LU0976567544.SGD","LU1633808545.USD","IE00B19Z8X17.USD","LU2462591350.SGD","LU0553294199.USD","BK4592","MARS","LU0124676726.USD","LU2242650005.HKD","IE00BD6J9T35.USD","IE000WAW04H5.SGD","BK4112","LU0345769631.USD","ILDR","SG9999017495.SGD","IE00BQXX3D17.EUR","LU2250418816.HKD","LU2106854487.HKD","FRSH","BK4585","LU0289960550.SGD","LU2133065610.SGD","GOOY","LU0265550946.USD","LU1861215975.USD","BK4576","LU0868494708.USD","LU0070217475.USD","LU0158827781.USD","IE00BWXC8680.SGD","LU0672654240.SGD","DSPC","LU1196500208.SGD","IE00BJTD4N35.SGD","AIPI","BK4514","LU0784385170.HKD","BK4023","LU1914381329.SGD","LU0052756011.USD","LU2271345857.HKD","LU1571399168.USD","LU0784385840.USD","LU0820561909.HKD","LU0149725797.USD","LU1430594728.SGD","LU1803068623.USD","LU0957791311.USD","BK4532","TEMT","LU2023250330.USD","LU1046421795.USD","LU1201861249.SGD","LU1481011911.USD","LU0795875086.SGD","LU1732800096.USD","LU0472753341.HKD","IE00BDGV0183.EUR","LU2357305700.SGD","LU2506951958.HKD","IE0004091025.USD","LU2430703251.USD","IE00BVYPNP33.GBP","LOFF","IE0000B7K699.USD","LU1989764748.USD","LU2362541513.USD","SG9999014906.USD","LU1778281490.HKD","IE00BQXX3C00.GBP","LU0106261372.USD","LU2247934214.USD","LU0742534661.SGD","LU0345774631.USD","LU1267930227.SGD","LU1868837136.USD","LU1301847155.USD","WARP","LU2456880835.USD","IE00BKVL7J92.USD","LU2506952097.USD","LU0187121727.USD","LU0889566641.SGD","ARMA","LU2023250843.SGD","LU1670628061.USD","LU2362541273.HKD","LU2756315664.SGD","IE0002270589.USD","LU2462591277.SGD","LU2125909593.SGD","LOFD","LU0011850046.USD","GOOGL","LU1059921491.USD","SG9999014542.SGD","SGXZ81514606.USD","BK4561","LU0345768740.USD","BK4512","LU1244550221.USD","BK4533","GB00BDT5M118.USD","LU1121112475.USD","LU0689472784.USD","IE00BDCRKT87.USD","LU0466842654.USD","IE0001KFT4U8.USD","IE00BYXW3230.USD","LU2420271590.USD","LU0511384066.AUD","LU0320765992.SGD","LU0127658192.USD","TRUC","LU0302445910.USD","LU0689626769.HKD","LU1894683264.USD","EFIV","LU2065169927.USD","LU0784384876.USD","IE00BMPRXQ63.HKD","LU1201861165.SGD","GOOW","LU2275660780.HKD","LU2023251221.USD","LU0823421416.USD","LU1951200564.SGD","LU1244550577.SGD","LU0320765059.SGD","LU2543165471.USD","QCMD","BK4534","LU0345774391.USD","LU1951198990.SGD","BK4605","LU2065170008.USD","LU2097344357.USD","LU0215105999.USD","LU2213496289.HKD","IE00BJTD4V19.USD","LU1280957306.USD","LU2433249047.HKD","BK4575","LU0980610538.SGD","LU1935043452.HKD","LU1852331112.SGD","LU2347655073.USD","LU2430703178.SGD","GOU","LU0130517989.USD","LU0174119429.USD","IE00BK4W5L77.USD","LU1935043023.USD","LU1917777945.USD","LU2237438978.USD","IE00BMPRXR70.SGD","METV","LU0964807845.USD","LU1720051017.SGD","IE00BJJMRZ35.SGD","IE00BK4W5M84.HKD","LU2168563687.JPY","LU1880398554.USD","IE00BVYPNW00.USD","LU2191332357.HKD","LU0256863902.USD","LU0130518102.USD","XDAT","LU0477156797.USD","LU1267930730.SGD","LU1235294995.USD","BK4515","LU2417539215.USD","LU2125154778.USD","IE00BJT1NW94.SGD","LU1400636657.SGD","HK0000532082.HKD","LU0784383803.USD","LU1244550494.USD","LU0795875169.SGD","LU2746668461.USD","LU0545562505.USD","SPCH","OBX","ASTX","GOGL","BK4550","SKYY","LU1720051108.HKD","LU0211326755.USD","BK4615","LU1642822529.SGD","LU2065171402.SGD","LU2097829019.USD","SGXZ51526630.SGD","LU1804176565.USD","CMAG","LU2462157665.USD","LU0354030438.USD","LU0070302665.USD","LU0128525929.USD","IE000M9KFDE8.USD","LU0787776722.HKD","LU2471134879.HKD","LU2242649171.HKD","BK4089","SSPC","LU2077746001.SGD","LU0426412945.USD","LU1839511570.USD","ARM","IE00B1BXHZ80.USD","LU1935042991.SGD","IE00BDRTCR15.USD","IE00B1XK9C88.USD","IE0009354923.USD","XLC","ELOL","LU2054465674.USD","LU1548497426.USD","IE00B19Z8W00.USD","BK4173","LU1823568750.SGD","SG9999014880.SGD","LU1267930573.SGD","SG9999014914.USD","LU2999663052.SGD","BK4543","LU0097036916.USD","LU1989772923.USD","LU0476273544.USD","LU0982800491.AUD","LU2404859667.USD","IE0034235295.USD","LU1815336760.USD","LU1366333091.USD","LU2491049909.HKD","LU0320765489.SGD","LU2023250504.SGD","LU1861558580.USD","LU1868836914.USD","LU1923622614.USD","LU0276348264.USD","LU1815333072.USD","BK4554","LU1066051498.USD","LU1868836757.USD","LU1069344957.HKD","SG9999015945.SGD","IE00BFMHRM44.USD","LU0061475181.USD","LU0266013472.USD","LIFE","LU1145028129.USD","BLCK","LU2211815571.USD","IE00BBT3K403.USD","BK4563","SG9999015986.USD","LU1035775433.USD","LU1935042215.USD","ASTY","LU2111349929.HKD","LU1974910355.USD","BK4613","LU1718418525.SGD","LU0731783394.SGD","BK4503","CANC","HEAL","IE0002141913.USD","LU2168564065.EUR","LU0130102774.USD","LU0006306889.USD","LU0234572021.USD","IE00BZ1G4Q59.USD","LU1144417596.USD","LU0323591593.USD","LU0477156953.USD","BK4527","LU1935043536.SGD","LU1923623000.USD","TDV","SG9999015358.SGD","PLU","BK4538","WTRE","LU0950375773.USD","LU1066051225.USD","GGLL","SG9999002232.USD","LU0077335932.USD","LU1221951046.USD","SG9999002224.SGD","LU0690374615.EUR","HK0000304805.HKD","BBH","LU0081259029.USD","IE00BGHQDM52.EUR","LU0345768153.USD","LU0096364046.USD","BK4230","IE00B2B36J28.USD","IE00BKDWB100.SGD","LU2750360641.GBP","SPCX","LU2471134523.USD","LU0557290698.USD","TEM","LU0109391861.USD","TRFK","SG9999018857.SGD","LU1645745479.HKD","LU0345770993.USD","HK0000304797.USD","LU1880398471.USD","SGXZ31699556.SGD","LU0882574139.USD","ARMU","BK4097","LU1496350171.SGD","BK4609","LU0170899867.USD","LU1119994496.HKD","LU1303367103.USD","LU1236620834.HKD","QCML","LU0143551892.USD","LU0175139822.USD","LU0354030511.USD","ARMG","AUTL","LU0444971666.USD","QCMU","LU2746668974.SGD","LU1894683348.USD","LU2954938101.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681611866","title":"Tempus AI, Inc. (NASDAQ:TEM) Just Reported And Analysts Have Been Lifting Their Price Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=2681611866","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681611866?lang=en_us&edition=fundamental","pubTime":"2026-11-06 20:29","pubTimestamp":1793968185,"startTime":"0","endTime":"0","summary":"SSimply Wall StNovember 6, 2026","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/9551728-choice2-card/1789016329041","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/9551728-choice2-card/1789016329041"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/tempus-ai-inc-nasdaqtem-just-reported-and-analysts-have-been","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/tempus-ai-inc-nasdaqtem-just-reported-and-analysts-have-been","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ARKG","LU1861559042.SGD","TEMC","LU1861558580.USD","BK4121","BK4611","HEAL","TEMT","BK4613","TEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681508887","title":"Recursion Stock Gets A Lift From Trial Progress And New Board Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2681508887","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681508887?lang=en_us&edition=fundamental","pubTime":"2026-11-06 09:24","pubTimestamp":1793928243,"startTime":"0","endTime":"0","summary":"SSasha JovanovicNovember 6, 2026","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/recursion-stock-gets-a-lift-from-trial-progress-and-new-boar","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/recursion-stock-gets-a-lift-from-trial-progress-and-new-boar","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4539","BK4609","BK4548","RXRX","BK4139","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681202102","title":"Beam Therapeutics Inc. : Jonestrading Assumes Coverage with Buy Rating; Target Price $35","url":"https://stock-news.laohu8.com/highlight/detail?id=2681202102","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681202102?lang=en_us&edition=fundamental","pubTime":"2026-11-05 19:51","pubTimestamp":1793879510,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nFWN46M2PV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1861559042.SGD","BEAM","LU1861558580.USD","BK4588","BK4611","BK4139","BK4535","BK4556","BK4505","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681099176","title":"Recursion Pharmaceuticals Grants Director Fred Hassan 156,658 Restricted Stock Units","url":"https://stock-news.laohu8.com/highlight/detail?id=2681099176","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681099176?lang=en_us&edition=fundamental","pubTime":"2026-11-05 06:39","pubTimestamp":1793831977,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals Grants Director Fred Hassan 156,658 Restricted Stock UnitsRecursion Pharmaceuticals awarded director Fred Hassan 156,658 shares of Class A Common Stock on Nov. 2, 2026.Discla","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nNDL67WLD5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4609","RXRX","BK4539","BK4139","BK4611","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681099179","title":"Recursion Pharmaceuticals Director Blake Borgeson Reports Sale of $155,200 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2681099179","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681099179?lang=en_us&edition=fundamental","pubTime":"2026-11-05 06:39","pubTimestamp":1793831963,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals Director Blake Borgeson Reports Sale of $155,200 in Common SharesRecursion Pharmaceuticals director Blake Borgeson sold 40,000 shares of Class A Common Stock on November 3, 2","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nNDL9Vnswb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Recursion Pharmaceuticals Director Blake Borgeson Reports Sale of $155,200 in Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4609","RXRX","BK4539","BK4611","BK4139","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681935960","title":"Tempus AI Director David R Epstein Reports Sale of Common Shares Worth $27,487.30","url":"https://stock-news.laohu8.com/highlight/detail?id=2681935960","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681935960?lang=en_us&edition=fundamental","pubTime":"2026-11-05 05:31","pubTimestamp":1793827902,"startTime":"0","endTime":"0","summary":"Tempus AI Director David R Epstein Reports Sale of Common Shares Worth $27,487.30Tempus AI director David R. Epstein sold 370 Class A Common Stock shares on November 2, 2026.The sale price was $74.29 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nNDL64spNd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Tempus AI Director David R Epstein Reports Sale of Common Shares Worth $27,487.30","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","LU1861558580.USD","LU1861559042.SGD","TEMC","BK4611","TEMT","BK4613","ARKG","TEM","HEAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681674400","title":"Personalis Q3 Revenue Beat on Increased Test Volume; Suspends Forecast on Pending Tempus AI Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2681674400","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681674400?lang=en_us&edition=fundamental","pubTime":"2026-11-05 05:09","pubTimestamp":1793826549,"startTime":"0","endTime":"0","summary":"Personalis Q3 revenue beat on increased test volume; suspends forecast on pending Tempus AI mergerOverviewPrecision oncology genomics firm's Q3 revenue rose yr/yr, beating analyst expectationsRevenue ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL2N46L1CI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","LU1861558580.USD","LU1861559042.SGD","TEMC","BK4611","PSNL","TEMT","BK4613","ARKG","TEM","HEAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680576900","title":"Crispr Therapeutics Presents Zugo-Cel Lymphoma Data at ASH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2680576900","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680576900?lang=en_us&edition=fundamental","pubTime":"2026-11-04 22:11","pubTimestamp":1793801478,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics Presents Zugo-cel Lymphoma Data at ASH Annual MeetingCRISPR Therapeutics will present zugo-cel clinical data at the American Society of Hematology annual meeting, Dec. 12-15, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nNDL2lcNyd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","SG9999014021.USD","BK4139","SG9999014013.SGD","BK4556","LU2210150020.SGD","IE00BQXX3C00.GBP","IE00BQXX3D17.EUR","IE00BN0W2T93.GBP","BK4585","ARKG","LU1861558580.USD","IE00BN0W2V16.EUR","BK4611","LU2095319765.USD","NDAQ","SG9999014039.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","SG9999014005.SGD","BK4112","IE00BKPKM429.USD","BCDF","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BQXX3F31.USD","CRSP","LU1861559042.SGD","BK4588","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680576820","title":"Beam Therapeutics Reports Improved Patient-Reported Outcomes in Risto-Cel Sickle Cell Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2680576820","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680576820?lang=en_us&edition=fundamental","pubTime":"2026-11-04 22:10","pubTimestamp":1793801458,"startTime":"0","endTime":"0","summary":"Beam Therapeutics Reports Improved Patient-Reported Outcomes in Risto-cel Sickle Cell TrialBeam Therapeutics will present updated Phase 1/2 BEACON trial results for sickle cell therapy risto-cel at AS","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nNDL5K35zW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","LU1861559042.SGD","BK4588","LU2210149790.SGD","IE00BQXX3C00.GBP","IE00BN0W2T93.GBP","SG9999014021.USD","BK4112","LU1861558580.USD","BK4585","BEAM","IE00B64PRP62.GBP","IE00BKPKM429.USD","SG9999014039.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","BK4505","LU0314104364.USD","LU2210150020.SGD","IE00BN0W2W23.USD","SG9999014005.SGD","IE00BQXX3F31.USD","NDAQ","LU2095319765.USD","BCDF","BK4611","BK4139","BK4556","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680054774","title":"Clene Posts Q3 Profit on Warrant Liability Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2680054774","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680054774?lang=en_us&edition=fundamental","pubTime":"2026-11-04 21:37","pubTimestamp":1793799455,"startTime":"0","endTime":"0","summary":"Clene posts Q3 profit on warrant liability gainsOverviewUS biopharma firm's Q3 net income reached $3.9 mln, reversing a year-ago lossOperating expenses rose 13% yr/yr, mainly due to NDA-related regula","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL2N46L0T2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLNN","BK4611","BK4535","LU1861558580.USD","BK4556","BK4588","BEAM","BK4585","BK4505","BK4139","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680054565","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Alkermes (ALKS), Nurix Therapeutics (NRIX) and Beam Therapeutics (BEAM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2680054565","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680054565?lang=en_us&edition=fundamental","pubTime":"2026-11-04 21:20","pubTimestamp":1793798459,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alkermes (ALKS), Nurix Therapeutics (NRIX) and Bea...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-alkermes-alks-nurix-therapeutics-nrix-and-beam-therapeutics-beam-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-alkermes-alks-nurix-therapeutics-nrix-and-beam-therapeutics-beam-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861558580.USD","LU1861559042.SGD","PSCH","LABU","LU0029874061.USD","FBT","IBRN","BK4611","BEAM","BK4137","BK4505","ALKS","LU0128526141.USD","HCSG","XBI","BK4535","BK4581","NRIX","PSIL","BK4556","XLV","MEDX","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680056273","title":"Beam Therapeutics Inc. : Wedbush Raises Target Price to $30 from $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2680056273","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680056273?lang=en_us&edition=fundamental","pubTime":"2026-11-04 20:30","pubTimestamp":1793795443,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nFWN46L2JV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","BK4139","BK4611","BEAM","BK4505","LU1861558580.USD","BK4588","BK4556","BK4585","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680805612","title":"Viridian Posts First Lumvoa Revenue but Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2680805612","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680805612?lang=en_us&edition=fundamental","pubTime":"2026-11-04 20:27","pubTimestamp":1793795254,"startTime":"0","endTime":"0","summary":"Viridian posts first Lumvoa revenue but net loss widensOverviewU.S. biotech firm reported first net product revenue from Lumvoa after TED launch in Q3Q3 net loss widened to $101.2 mln from $34.6 mln a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL2N46L0MP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRDN","LU1861558580.USD","BK4007","ARVN","LU1861559042.SGD","BK4535","BK4139","BK4588","BEAM","BK4585","BK4556","BK4611","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680561550","title":"Ocugen Q3 Revenue Beats Expectations, Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2680561550","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680561550?lang=en_us&edition=fundamental","pubTime":"2026-11-04 20:25","pubTimestamp":1793795138,"startTime":"0","endTime":"0","summary":"Ocugen Q3 revenue beats expectations, net loss narrowsOverviewUS gene therapy developer's Q3 revenue rose and beat analyst expectationsNet loss per share for Q3 narrowed to $0.01 from $0.07 last yearC","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL2N46L0MC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCGN","BK4556","BK4585","CRSP","BK4563","LU1861559042.SGD","BK4139","QURE","LU1861558580.USD","LU0889565916.HKD","BK4588","BK4568","LU0109394709.USD","LU0320765992.SGD","ARKG","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680056386","title":"Switzerland's MoonLake Q3 Net Loss Widens as R&D Costs Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2680056386","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680056386?lang=en_us&edition=fundamental","pubTime":"2026-11-04 20:18","pubTimestamp":1793794714,"startTime":"0","endTime":"0","summary":"Switzerland's MoonLake Q3 net loss widens as R&D costs riseOverviewSwitzerland biotech posted Q3 net loss as R&D expenses rose on milestone license feesCompany submitted Biologics License Application ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL2N46L0M4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARKG","BK4611","CRSP","BK4556","LU0109394709.USD","MLTX","LU0889565916.HKD","QURE","BK4139","BK4588","LU1861558580.USD","BK4585","LU1861559042.SGD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680405688","title":"AC Immune Q3 Net Loss Narrows as Revenue Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2680405688","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680405688?lang=en_us&edition=fundamental","pubTime":"2026-11-04 20:15","pubTimestamp":1793794559,"startTime":"0","endTime":"0","summary":"AC Immune Q3 net loss narrows as revenue risesOverviewSwitzerland-based neurodegenerative disease biopharma's Q3 revenue rose, driven by Takeda arrangement revenueNet loss for Q3 narrowed to CHF 8.8 m","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL2N46L0LY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BK4585","BK4588","CRSP","LU1861559042.SGD","ACIU","BK4611","LU1861558580.USD","ARKG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680055796","title":"Nuvectis Pharma Q3 Net Loss Widens on Licensing and R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2680055796","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680055796?lang=en_us&edition=fundamental","pubTime":"2026-11-04 20:12","pubTimestamp":1793794325,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma Q3 net loss widens on licensing and R&D costsOverviewUS biopharma firm's Q3 net loss widened, driven by upfront licensing payments and higher R&D spendCompany ended Q3 with $140.7 mln ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL2N46L0MH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","BK4505","BK4585","BK4588","CMPS","LU1861559042.SGD","BK4139","NVCT","BK4611","LU1861558580.USD","BEAM","BK4556","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680055676","title":"Q32 Bio Q3 Net Loss Widens on Higher R&D and Admin Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2680055676","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680055676?lang=en_us&edition=fundamental","pubTime":"2026-11-04 20:06","pubTimestamp":1793794017,"startTime":"0","endTime":"0","summary":"Q32 Bio Q3 net loss widens on higher R&D and admin costsOverviewUS biotech firm's Q3 net loss widened yr/yr on higher R&D and admin expensesCompany ended Q3 with $289.6 mln in cash after $200 mln publ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL2N46L0LN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BEAM","BK4588","BK4535","BK4505","LU1861558580.USD","QTTB","BK4556","BK4139","BK4611","LU1861559042.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":104,"code":"91000000","status":"200"}]}}